

Reviewer's Comment:

I have 3 important corrections.

Introduction

PV is characterized by excess production of red blood cells and ET is caused by overproduction of platelets □ please change this sentence into □

Dameshek (1950) proposed two highly speculative possibilities as the cause of trilinear polycythemia vera (PV) of erythrocythemia, thrombocythemia, granulocythemia: first, excessive bone marrow (BM) stimulation by an

unknown factor or second, by the lack or diminution of an inhibitory factor²⁻⁵. This hypothesis of PV as a trilinear myeloproliferative disorder of megakaryocytic, erthrocytic and granulocytic myeloproliferation was proven by Vainchenker (2005) to be correct by the discovery of the somatic JAK2V617F mutation as the driver cause of trilinear myeloproliferative neoplasms (MPNs) including PV, ET and secondary mylofibrosis (MF)²⁻⁶.

Conclusion

Philadelphia-negative □ please delete this word.

In MF □ please change into □ In JAK2, MPL and CALR mutated MF patients, additional mutations

Author Feedback

1- Lines indicated highlighted in yellow are my additions and corrections.

2- One more reference was added and therefore the order of the references changed.

3. In Introduction session:

The sentence 'PV is characterized by excess production of red blood cells and ET is caused by overproduction of platelets' was revised as follows: Dameshek W. proposed two highly speculative possibilities as the cause of trilinear PV of erythrocythemia, thrombocythemia, granulocythemia: excessive bone marrow stimulation by an unknown factor or the lack or decrease of an inhibitory factor. ² In 2005, James C. et al, who demonstrated that the somatic JAK2V617F mutation was the driver cause of trilinear MPNs including PV, ET and secondary MF, confirmed the hypothesis of PV as a trilinear myeloproliferative disorder of megakaryocytic, erthrocytic and granulocytic myeloproliferation. ³

4. In ASXL1 session

The following sentence was added:

A recent study by Tefferi A. et al. reported that ASXL1 mutation showed a significant association with shortened survival in a total of 570 MF patients (277 patients from Mayo Clinic and 293 from the University of Florence).¹⁰⁷

In Conclusion session:

5a. The word 'Philadelphia-negative' was deleted.

5b. The sentence 'In MF, mutations in genes such as ASXL1, EZH2, IDH1/2 and SRSF2 were associated with a poorer survival and increased leukemic transformation' was revised as follows: In JAK2, MPL and CALR-mutated MF patients, additional mutations in genes such as ASXL1, EZH2, IDH1/2 and SRSF2 were associated with a poorer survival and increased leukemic transformation